Eisai Creates US Subsidiary H3 Biomedicine with up to $200M

Jan 28, 2011

NEW YORK (GenomeWeb News) – Japanese drug firm Eisai has launched US subsidiary H3 Biomedicine with up to $200 million in funding to develop new oncology drugs based on patient genetic information.

Based in Cambridge, Mass., H3 Biomedicine aims to take a personalized medicine approach to developing such drugs by leveraging new insights into the genetic basis of cancer and advances in modern chemistry.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Letter Urges New Inquiry

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

Great Apes Get Shots, Too

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Woodcock on Vaccines, More

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

Science Paper Examines Molecular Contributors to Kidney Fibrosis

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.

Featured White Papers

Five Questions To Consider For Variable Print

Analyze, Interpret and Report NGS Data Faster than Ever Before

Increase diagnostic yield with class-leading variant prioritization

Using Parallel Evaporators to Escalate COVID-19 Test Kit Preparation

Mar

09

Featured Webinar

Implementation of Whole-Exome and Virtual Panel Testing for Rare Disease at a Children’s Hospital

The growth of next-generation sequencing (NGS) testing presents both opportunities and challenges for clinical, informatics, and laboratory teams.

Mar

16

Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community.

Mar

30

Featured Webinar

Circulating Tumor Cells in Breast Cancer: Understanding a Validated Diagnostic Tool for Precision Medicine

This webinar will provide an overview of the current state of circulating tumor cell (CTC) enumeration for clinical use in metastatic breast cancer.

Mar

31

Featured Webinar

Development and Commercialization of a Novel CRISPR-Based SARS CoV-2 Test

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.

Menu

Eisai Creates US Subsidiary H3 Biomedicine with up to $200M

To read the full story....

Breaking News

FDA Issues EUA for Adaptive Biotechnologies COVID-19 T-Cell Response Test

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

Fauna Bio Gets $373K NIH Grant to Study Animal Genomes for Potential Drug Targets

New Products Posted to GenomeWeb: Purigen Biosystems, Zymo Research, Qiagen, More

People in the News: New Appointments at Precipio, ERS Genomics, Omniome, PierianDx, More

In Brief This Week: Invenio Genetics, Swift Biosciences, Caris Life Sciences, and More

The Scan

Letter Urges New Inquiry

Great Apes Get Shots, Too

Woodcock on Vaccines, More

Science Paper Examines Molecular Contributors to Kidney Fibrosis

Featured White Papers

Implementation of Whole-Exome and Virtual Panel Testing for Rare Disease at a Children’s Hospital

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Circulating Tumor Cells in Breast Cancer: Understanding a Validated Diagnostic Tool for Precision Medicine

Development and Commercialization of a Novel CRISPR-Based SARS CoV-2 Test

Sponsorships